ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $25.03 million. The enterprise value is $28.67 million.
Important Dates
The last earnings date was Wednesday, April 30, 2025, after market close.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 16.25 million shares outstanding. The number of shares has increased by 118.45% in one year.
| Current Share Class | 16.25M |
| Shares Outstanding | 16.25M |
| Shares Change (YoY) | +118.45% |
| Shares Change (QoQ) | +13.36% |
| Owned by Insiders (%) | 16.62% |
| Owned by Institutions (%) | 1.77% |
| Float | 13.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.98 |
| Forward PS | n/a |
| PB Ratio | 3.71 |
| P/TBV Ratio | 4.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 56.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.22, with a Debt / Equity ratio of 0.36.
| Current Ratio | 0.22 |
| Quick Ratio | 0.03 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.95 |
Financial Efficiency
Return on equity (ROE) is -42.42% and return on invested capital (ROIC) is -15.21%.
| Return on Equity (ROE) | -42.42% |
| Return on Assets (ROA) | -10.91% |
| Return on Invested Capital (ROIC) | -15.21% |
| Return on Capital Employed (ROCE) | -31.43% |
| Revenue Per Employee | $26,757 |
| Profits Per Employee | -$153,198 |
| Employee Count | 19 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -110,539 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.19% in the last 52 weeks. The beta is 0.06, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +95.19% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 61.05 |
| Average Volume (20 Days) | 332,633 |
Short Selling Information
The latest short interest is 444,395, so 2.73% of the outstanding shares have been sold short.
| Short Interest | 444,395 |
| Short Previous Month | 317,388 |
| Short % of Shares Out | 2.73% |
| Short % of Float | 3.29% |
| Short Ratio (days to cover) | 1.73 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $508,384 and -$2.91 million in losses. Loss per share was -$0.22.
| Revenue | 508,384 |
| Gross Profit | 507,898 |
| Operating Income | -2.56M |
| Pretax Income | -12.37M |
| Net Income | -2.91M |
| EBITDA | -2.52M |
| EBIT | -2.56M |
| Loss Per Share | -$0.22 |
Full Income StatementBalance Sheet
The company has $217,258 in cash and $2.88 million in debt, giving a net cash position of -$2.66 million or -$0.16 per share.
| Cash & Cash Equivalents | 217,258 |
| Total Debt | 2.88M |
| Net Cash | -2.66M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 7.96M |
| Book Value Per Share | 0.37 |
| Working Capital | -5.26M |
Full Balance SheetCash Flow
| Operating Cash Flow | -1.39M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.39M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
| Gross Margin | 99.90% |
| Operating Margin | -503.55% |
| Pretax Margin | -666.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |